



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417
E: co.secretary@biocon.com

www.biocon.com

BIO/SECL/TG/2026-27/75

October 26, 2026

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 051
Scrip Code - 532523	Scrip Symbol - BIOCON

Subject: Company Statement

Dear Sir/Madam,

Please find enclosed Company Statement w.r.t. **“Biocon Secures Market Entry for Yesintek™, a Proposed Biosimilar to Stelara®, in Additional Global Markets”**.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

RAJESH
UMAKANT
SHANOE

Digitally signed by
RAJESH UMAKANT
SHANOE
Date: 2026.10.26
08:24:07 +05'30'

Rajesh U. Shanoy
Company Secretary and Compliance Officer
M. No.: ACS 16328

Encl: Company Statement



NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Biocon Secures Market Entry for Yesintek™, a Proposed Biosimilar to Stelara®, in Additional Global Markets

Bengaluru, Karnataka, India, October 26, 2026

Biocon Limited (BSE code: 532523, NSE: BIOCON) has signed a license agreement with Janssen Sciences Ireland clearing the way for the commercialization of Yesintek™, its proposed biosimilar to Stelara® (Ustekinumab), in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan with immediate effect.

This milestone builds on the Company's previously announced agreements with Janssen that secured market entry dates for Yesintek™ in the [United States](#), and in [Europe, the UK, Canada and Japan](#).

These additional market entry rights for biosimilar Ustekinumab will allow Biocon to offer an affordable and effective treatment option for patients impacted by autoimmune diseases in these markets.

Yesintek™ is a human interleukin-12 and -23 antagonist that disrupts IL-12 and IL-23 mediated signalling in immune mediated diseases and has been approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. The reference brand, Stelara®, had worldwide sales of \$6.08 billion in 2025[^].

[^]Johnson & Johnson Reported 2025 Sales

Note:

- All trademarks, registered or unregistered, are the property of their respective owners.
- Product launches in all the countries / regions are subject to regulatory approval.

Forward-Looking Statement: Statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update these statements except as required by law.